Alnylam wins FDA approval of rare disease drug in step toward profitability

Alnylam Pharmaceuticals on Monday said the Food and Drug Administration has approved a new drug it’s been developing for the rare genetic disease transthyretin amyloidosis and that’s viewed by analysts as important to the company’s goal of becoming sustainably profitable.